Continuum Advisory LLC acquired a new position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 15,277 shares of the company’s stock, valued at approximately $1,253,000.
Other large investors have also modified their holdings of the company. Laurel Wealth Advisors LLC purchased a new stake in shares of GE HealthCare Technologies during the fourth quarter worth approximately $26,000. Optima Capital LLC purchased a new stake in shares of GE HealthCare Technologies during the fourth quarter worth approximately $27,000. Godfrey Financial Associates Inc. purchased a new stake in shares of GE HealthCare Technologies during the fourth quarter worth approximately $27,000. Montag A & Associates Inc. increased its stake in shares of GE HealthCare Technologies by 105.4% during the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock worth $28,000 after buying an additional 175 shares during the period. Finally, Maseco LLP purchased a new stake in shares of GE HealthCare Technologies during the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.
GE HealthCare Technologies Stock Performance
Shares of GEHC opened at $64.67 on Friday. The stock has a 50 day moving average price of $66.89 and a 200 day moving average price of $75.49. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95. The company has a market capitalization of $29.42 billion, a price-to-earnings ratio of 15.47, a price-to-earnings-growth ratio of 1.44 and a beta of 0.74. GE HealthCare Technologies Inc. has a 52-week low of $58.75 and a 52-week high of $89.77.
Insider Transactions at GE HealthCare Technologies
In other GE HealthCare Technologies news, Director Rodney F. Hochman purchased 1,618 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average cost of $62.03 per share, with a total value of $100,364.54. Following the completion of the acquisition, the director directly owned 1,618 shares of the company’s stock, valued at $100,364.54. This trade represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Saccaro purchased 3,310 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was acquired at an average cost of $60.60 per share, with a total value of $200,586.00. Following the completion of the acquisition, the chief financial officer directly owned 87,471 shares of the company’s stock, valued at $5,300,742.60. This represents a 3.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 21,847 shares of company stock valued at $1,361,355 over the last three months. 0.36% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of research firms recently weighed in on GEHC. BNP Paribas Exane cut their target price on shares of GE HealthCare Technologies from $95.00 to $88.00 in a research note on Friday, May 1st. Wells Fargo & Company cut their target price on shares of GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Citigroup cut their target price on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings lowered shares of GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Finally, HSBC cut their target price on shares of GE HealthCare Technologies from $100.00 to $90.00 in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $80.21.
Check Out Our Latest Report on GE HealthCare Technologies
About GE HealthCare Technologies
GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.
In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.
Read More
- Five stocks we like better than GE HealthCare Technologies
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report).
Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
